Mass General Brigham vetoes controversial Alzheimer's drug Aduhelm after internal review

Mass General Brigham is the latest big-name health system to announce it will not be treating its patients with Biogen’s Aduhelm, the controversial Alzheimer’s disease drug cleared by the Food and Drug Administration in June.